<DOC>
	<DOCNO>NCT02267343</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety ONO-4538 patient unresectable advanced recurrent gastric cancer ( include esophagogastric junction cancer ) refractory intolerant standard therapy .</brief_summary>
	<brief_title>Study ONO-4538 Unresectable Advanced Recurrent Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Men &amp; woman â‰¥20 year age Unresectable advanced recurrent gastric cancer ( include esophagogastric junction cancer ) Histologically confirm adenocarcinoma Refractory intolerant standard therapy ECOG Performance Status score 0 1 A life expectancy least 3 month Current past history severe hypersensitivity antibody product Patients multiple primary cancer Patients metastasis brain meninx symptomatic require treatment Patients active , know suspected autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>